Antidepressant effects of the muscarinic cholinergic receptor antagonist scopolamine: A review

Biological Psychiatry

Volumn 73, Issue 12, 2013, Pages 1156-1163

  Drevets, Wayne C ^a   Zarate Jr , Carlos A ^b   Furey, Maura L ^b  

^a University of Oklahoma Tulsa College of Medicine   (United States)

^b NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

Author keywords

Antidepressant; bipolar; cholinergic; muscarinic; scopolamine; unipolar

Indexed keywords

ANTIDEPRESSANT AGENT; SCOPOLAMINE;

ANTIDEPRESSANT ACTIVITY; BIPOLAR DEPRESSION; BLURRED VISION; CHOLINERGIC ACTIVITY; CHOLINERGIC SYSTEM; DELIRIUM; DIASTOLIC BLOOD PRESSURE; DIZZINESS; DROWSINESS; DRUG EFFICACY; ELECTROCONVULSIVE THERAPY; GENE EXPRESSION; HAMILTON ANXIETY SCALE; HEART RATE; HUMAN; HYPOMANIA; MAJOR DEPRESSION; MONTGOMERY ASBERG DEPRESSION RATING SCALE; MOOD DISORDER; NERVE CELL PLASTICITY; NEUROBIOLOGY; PRIORITY JOURNAL; PROFILE OF MOOD STATES; PSYCHOSIS; REMISSION; REVIEW; SIDE EFFECT; SUICIDAL IDEATION; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; TREATMENT RESPONSE; XEROSTOMIA; YOUNG MANIA RATING SCALE;

ADOLESCENT; ADULT; ANTIDEPRESSIVE AGENTS; DEPRESSION; FEMALE; HUMANS; MALE; MIDDLE AGED; MUSCARINIC ANTAGONISTS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SCOPOLAMINE HYDROBROMIDE; YOUNG ADULT;

EID: 84878420520     PISSN: 00063223     EISSN: 18732402     Source Type: Journal    
DOI: 10.1016/j.biopsych.2012.09.031     Document Type: Review

References (75)

1. R.M. Berman, A. Cappiello, A. Anand, D.A. Oren, G.R. Heninger, D.S. Charney, and J.H. Krystal Antidepressant effects of ketamine in depressed patients Biol Psychiatry 47 2000 351 354
2. C.A. Zarate Jr, J.B. Singh, P.J. Carlson, N.E. Brutsche, R. Ameli, and D.A. Luckenbaugh A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression Arch Gen Psychiatry 63 2006 856 864
3. H. Giedke, and F. Schwarzler Therapeutic use of sleep deprivation in depression Sleep Med Rev 6 2002 361 377
4. R.C. Shelton, and P.T. Loosen Sleep deprivation accelerates the response to nortriptyline Prog Neuropsychopharmacol Biol Psychiatry 17 1993 113 123
5. J.C. Wu, J.R. Kelsoe, C. Schachat, B.G. Bunney, A. DeModena, and S. Golshan Rapid and sustained antidepressant response with sleep deprivation and chronotherapy in bipolar disorder Biol Psychiatry 66 2009 298 301
6. D.S. Janowsky, M.K. el-Yousef, J.M. Davis, and H.J. Sekerke A cholinergic-adrenergic hypothesis of mania and depression Lancet 2 1972 632 635
7. J.L. Davis, L.K. Gerbrandt, and A. Cherkin Retroactive amnesia induced in chicks by the proline analog L-baikiain, without EEG seizures or depression Physiol Behav 21 1978 653 658
8. D.S. Janowsky, M.K. el-Yousef, and J.M. Davis Acetylcholine and depression Psychosom Med 36 1974 248 257
9. J.I. Nurnberger Jr, D.C. Jimerson, S. Simmons-Alling, C. Tamminga, N.S. Nadi, and D. Lawrence Behavioral, physiological, and neuroendocrine responses to arecoline in normal twins and "well state" bipolar patients Psychiatry Res 9 1983 191 200
10. S.C. Risch, N.H. Kalin, and D.S. Janowsky Cholinergic challenges in affective illness: Behavioral and neuroendocrine correlates J Clin Psychopharmacol 1 1981 186 192
11. S.C. Dilsaver Pathophysiology of "cholinoceptor supersensitivity" in affective disorders Biol Psychiatry 21 1986 813 829
12. D.S. Janowsky, S.C. Risch, L.Y. Huey, B. Kennedy, and M. Ziegler Effects of physostigmine on pulse, blood pressure, and serum epinephrine levels Am J Psychiatry 142 1985 738 740
13. R.T. Rubin, S.M. O'Toole, M.E. Rhodes, L.K. Sekula, and R.K. Czambel Hypothalamo-pituitary-adrenal cortical responses to low-dose physostigmine and arginine vasopressin administration: Sex differences between major depressives and matched control subjects Psychiatry Res 89 1999 1 20
14. M. Berger, D. Riemann, D. Hochli, and R. Spiegel The cholinergic rapid eye movement sleep induction test with RS-86. State or trait marker of depression? Arch Gen Psychiatry 46 1989 421 428
15. J.C. Gillin, N. Sitaram, and W.C. Duncan Muscarinic supersensitivity: A possible model for the sleep disturbance of primary depression? Psychiatry Res 1 1979 17 22
16. D. Riemann, F. Hohagen, S. Krieger, H. Gann, W.E. Muller, and R. Olbrich Cholinergic REM induction test: Muscarinic supersensitivity underlies polysomnographic findings in both depression and schizophrenia J Psychiatr Res 28 1994 195 210
17. D.M. Cannon, J.K. Klaver, S.K. Gandhi, G. Solorio, S.A. Peck, and K. Erickson Genetic variation in cholinergic muscarinic-2 receptor gene modulates M2 receptor binding in vivo and accounts for reduced binding in bipolar disorder Mol Psychiatry 16 2011 407 418
18. D.E. Comings, S. Wu, M. Rostamkhani, M. McGue, W.G. Iacono, and J.P. MacMurray Association of the muscarinic cholinergic 2 receptor (CHRM2) gene with major depression in women Am J Med Genet 114 2002 527 529
19. J.C. Wang, A.L. Hinrichs, H. Stock, J. Budde, R. Allen, and S. Bertelsen Evidence of common and specific genetic effects: Association of the muscarinic acetylcholine receptor M2 (CHRM2) gene with alcohol dependence and major depressive syndrome Hum Mol Genet 13 2004 1903 1911
20. D. Riemann, F. Hohagen, M. Bahro, and M. Berger Sleep in depression: The influence of age, gender and diagnostic subtype on baseline sleep and the cholinergic REM induction test with RS 86 Eur Arch Psychiatry Clin Neurosci 243 1994 279 290
21. R.T. Rubin, S.A. Abbasi, M.E. Rhodes, and R.K. Czambel Growth hormone responses to low-dose physostigmine administration: Functional sex differences (sexual diergism) between major depressives and matched controls Psychol Med 33 2003 655 665
22. J.L. Pongrac, R.B. Gibbs, and D.B. Defranco Estrogen-mediated regulation of cholinergic expression in basal forebrain neurons requires extracellular-signal-regulated kinase activity Neuroscience 124 2004 809 816
23. R.B. Gibbs, R. Gabor, T. Cox, and D.A. Johnson Effects of raloxifene and estradiol on hippocampal acetylcholine release and spatial learning in the rat Psychoneuroendocrinology 29 2004 741 748
24. J.M. Daniel, and G.P. Dohanich Acetylcholine mediates the estrogen-induced increase in NMDA receptor binding in CA1 of the hippocampus and the associated improvement in working memory J Neurosci 21 2001 6949 6956
25. D.H. Overstreet, R.W. Russell, D.A. Hay, and A.D. Crocker Selective breeding for increased cholinergic function: Biometrical genetic analysis of muscarinic responses Neuropsychopharmacology 7 1992 197 204
26. C. Betin, F.V. DeFeudis, N. Blavet, and F. Clostre Further characterization of the behavioral despair test in mice: Positive effects of convulsants Physiol Behav 28 1982 307 311
27. R.G. Browne Effects of antidepressants and anticholinergics in a mouse "behavioral despair" test Eur J Pharmacol 58 1979 331 334
28. P.A. Newhouse, T. Sunderland, P.N. Tariot, H. Weingartner, K. Thompson, and A.M. Mellow The effects of acute scopolamine in geriatric depression Arch Gen Psychiatry 45 1988 906 912
29. J.C. Gillin, L. Sutton, C. Ruiz, D. Darko, S. Golshan, S.C. Risch, and D. Janowsky The effects of scopolamine on sleep and mood in depressed patients with a history of alcoholism and a normal comparison group Biol Psychiatry 30 1991 157 169
30. U. Ebert, M. Grossmann, R. Oertel, T. Gramatte, and W. Kirch Pharmacokinetic-pharmacodynamic modeling of the electroencephalogram effects of scopolamine in healthy volunteers J Clin Pharmacol 41 2001 51 60
31. M.L. Furey, and W.C. Drevets Antidepressant efficacy of the antimuscarinic drug scopolamine: A randomized, placebo-controlled clinical trial Arch Gen Psychiatry 63 2006 1121 1129
32. M.L. Furey The prominent role of stimulus processing: Cholinergic function and dysfunction in cognition Curr Opin Neurol 24 2011 364 370
33. M.L. Furey, P. Pietrini, and J.V. Haxby Cholinergic enhancement and increased selectivity of perceptual processing during working memory Science 290 2000 2315 2319
34. M.L. Furey, P. Pietrini, J.V. Haxby, and W.C. Drevets Selective effects of cholinergic modulation on task performance during selective attention Neuropsychopharmacology 33 2008 913 923
35. V. Martinez, V. Parikh, and M. Sarter Sensitized attentional performance and Fos-immunoreactive cholinergic neurons in the basal forebrain of amphetamine-pretreated rats Biol Psychiatry 57 2005 1138 1146
36. M. Sarter, C.L. Nelson, and J.P. Bruno Cortical cholinergic transmission and cortical information processing in schizophrenia Schizophr Bull 31 2005 117 138
37. K.A. Frey, R.A. Koeppe, G.K. Mulholland, D. Jewett, R. Hichwa, and R.L. Ehrenkaufer In vivo muscarinic cholinergic receptor imaging in human brain with [11C]scopolamine and positron emission tomography J Cereb Blood Flow Metab 12 1992 147 154
38. J. Hyttel, J.J. Larsen, A.V. Christensen, and J. Arnt Receptor-binding profiles of neuroleptics Psychopharmacology Suppl 2 1985 9 18
39. E. Richelson Antimuscarinic and other receptor-blocking properties of antidepressants Mayo Clin Proc 58 1983 40 46
40. D.J. Safer The concomitant effects of mild sleep loss and an anticholinergic drug Psychopharmacologia 17 1970 425 433
41. T. Sunderland, P.N. Tariot, R.M. Cohen, H. Weingartner, E.A. Mueller 3rd, and D.L. Murphy Anticholinergic sensitivity in patients with dementia of the Alzheimer type and age-matched controls. A dose-response study Arch Gen Psychiatry 44 1987 418 426
42. A.A. Nierenberg, and L.M. DeCecco Definitions of antidepressant treatment response, remission, nonresponse, partial response, and other relevant outcomes: A focus on treatment-resistant depression J Clin Psychiatry 62 suppl 16 2001 5 9
43. W.C. Drevets, and M.L. Furey Replication of scopolamine's antidepressant efficacy in major depressive disorder: A randomized, placebo-controlled clinical trial Biol Psychiatry 67 2009 432 438
44. M.L. Furey, A. Khanna, E.M. Hoffman, and W.C. Drevets Scopolamine produces larger antidepressant and antianxiety effects in women than in men Neuropsychopharmacology 35 2010 2479 2488
45. F.M. Quitkin, J.W. Stewart, and P.J. McGrath Gender differences in treatment response Am J Psychiatry 158 2001 1531 1533
46. C. Berlanga, and M. Flores-Ramos Different gender response to serotonergic and noradrenergic antidepressants. A comparative study of the efficacy of citalopram and reboxetine J Affect Disord 95 2006 119 123
47. S.G. Kornstein, A.F. Schatzberg, M.E. Thase, K.A. Yonkers, J.P. McCullough, and G.I. Keitner Gender differences in treatment response to sertraline versus imipramine in chronic depression Am J Psychiatry 157 2000 1445 1452
48. F. Martenyi, M. Dossenbach, K. Mraz, and S. Metcalfe Gender differences in the efficacy of fluoxetine and maprotiline in depressed patients: A double-blind trial of antidepressants with serotonergic or norepinephrinergic reuptake inhibition profile Eur Neuropsychopharmacol 11 2001 227 232
49. A. Khan, A.E. Brodhead, R.L. Kolts, and W.A. Brown Severity of depressive symptoms and response to antidepressants and placebo in antidepressant trials J Psychiatr Res 39 2005 145 150
50. M.E. Thase, A.R. Entsuah, and R.L. Rudolph Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors Br J Psychiatry 178 2001 234 241
51. M.T. Berlim, and G. Turecki Definition, assessment, and staging of treatment-resistant refractory major depression: A review of current concepts and methods Can J Psychiatry 52 2007 46 54
52. E.A. Deisenhammer, A.B. Whitworth, C. Geretsegger, I. Kurzthaler, S. Gritsch, and C.H. Miller Intravenous versus oral administration of amitriptyline in patients with major depression J Clin Psychopharmacol 20 2000 417 422
53. B.G. Pollock, J.M. Perel, R.S. Nathan, and D.J. Kupfer Acute antidepressant effect following pulse loading with intravenous and oral clomipramine Arch Gen Psychiatry 46 1989 29 35
54. L.L. Brunton Goodman & Gilman's The Pharmacological Basis of Therapeutics 11th ed. 2006 McGraw-Hill New York
55. B. Cusack, A. Nelson, and E. Richelson Binding of antidepressants to human brain receptors: Focus on newer generation compounds Psychopharmacology (Berl) 114 1994 559 565
56. E. Richelson Are receptor studies useful for clinical practice? J Clin Psychiatry 44 1983 4 9
57. S.H. Preskorn Clinical Pharmacology of Selective Serotonin Reuptake Inhibitors 1996 Professional Communications Inc Caddo, OK
58. I.M. Anderson SSRIS versus tricyclic antidepressants in depressed inpatients: a meta-analysis of efficacy and tolerability Depress Anxiety 7 suppl 1 1998 11 17
59. J.C. Gillin, J. Lauriello, J.R. Kelsoe, M. Rapaport, S. Golshan, W.M. Kenny, and L. Sutton No antidepressant effect of biperiden compared with placebo in depression: A double-blind 6-week clinical trial Psychiatry Res 58 1995 99 105
60. E. Richelson Cholinergic transduction F.E. Bloom, D.J. Kupfer, Psychopharmacology: The Fourth Generation of Progress 1995 Raven Press New York
61. Y. Tizabi, B. Getachew, A.H. Rezvani, S.R. Hauser, and D.H. Overstreet Antidepressant-like effects of nicotine and reduced nicotinic receptor binding in the Fawn-Hooded rat, an animal model of co-morbid depression and alcoholism Prog Neuropsychopharmacol Biol Psychiatry 33 2009 398 402
62. D.W. Wang, R.B. Zhou, and Y.M. Yao Role of cholinergic anti-inflammatory pathway in regulating host response and its interventional strategy for inflammatory diseases Chin J Traumatol 12 2009 355 364
63. D.H. Overstreet, E. Friedman, A.A. Mathe, and G. Yadid The Flinders Sensitive Line rat: A selectively bred putative animal model of depression Neurosci Biobehav Rev 29 2005 739 759
64. H.F. Liu, W.H. Zhou, X.H. Xie, J.L. Cao, J. Gu, and G.D. Yang [Muscarinic receptors modulate the mRNA expression of NMDA receptors in brainstem and the release of glutamate in periaqueductal grey during morphine withdrawal in rats] Sheng Li Xue Bao 56 2004 95 100
65. D.S. Janowsky, D.H. Overstreet, and J.I. Nurnberger Jr Is cholinergic sensitivity a genetic marker for the affective disorders? Am J Med Genet 54 1994 335 344
66. A. Rami, F. Ausmeir, J. Winckler, and J. Krieglstein Differential effects of scopolamine on neuronal survival in ischemia and glutamate neurotoxicity: Relationships to the excessive vulnerability of the dorsoseptal hippocampus J Chem Neuroanat 13 1997 201 208
67. J.H. Krystal, G. Sanacora, H. Blumberg, A. Anand, D.S. Charney, and G. Marek Glutamate and GABA systems as targets for novel antidepressant and mood-stabilizing treatments Mol Psychiatry 7 suppl 1 2002 S71 S80
68. N. Li, B. Lee, R.J. Liu, M. Banasr, J.M. Dwyer, and M. Iwata mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists Science 329 2010 959 964
69. Li N, Liu R-J, Aghajanian G, Duman RS (2011): Rapid antidepressant actions of scopolamine require mtor sig-naling and synaptogenesis. Program # 903.15/KK17. 2011 Neuroscience Meeting Planner. Washington, DC: Society for Neurosciences.
70. R.S. Duman, N. Li, R.J. Liu, V. Duric, and G. Aghajanian Signaling pathways underlying the rapid antidepressant actions of ketamine Neuropharmacology 62 2012 35 41
71. B. Moghaddam, B. Adams, A. Verma, and D. Daly Activation of glutamatergic neurotransmission by ketamine: A novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex J Neurosci 17 1997 2921 2927
72. S.M. Rawls, and J.F. McGinty Muscarinic receptors regulate extracellular glutamate levels in the rat striatum: An in vivo microdialysis study J Pharmacol Exp Ther 286 1998 91 98
73. L. Putcha, K.J. Tietze, D.W. Bourne, C.M. Parise, R.P. Hunter, and N.M. Cintron Bioavailability of intranasal scopolamine in normal subjects J Pharm Sci 85 1996 899 902
74. Voleti B, Navarria AM, Duman RS (2012): Identification of muscarinic receptor subtype(s) that mediate the rapid antidepressant effects of scopolamine. Program # 69.28/Y1. 2012 Neuroscience Meeting Planner. New Orleans, LA: Society for Neurosciences.
75. Z. Nachum, B. Shahal, A. Shupak, O. Spitzer, A. Gonen, and I. Beiran Scopolamine bioavailability in combined oral and transdermal delivery J Pharmacol Exp Ther 296 2001 121 123